Siponimod Cuts Risk of Disability Progression in Multiple Sclerosis

This article originally appeared here.
Share this content:
Siponimod Cuts Risk of Disability Progression in Multiple Sclerosis
Siponimod Cuts Risk of Disability Progression in Multiple Sclerosis

FRIDAY, March 23, 2018 (HealthDay News) -- For patients with secondary progressive multiple sclerosis, the selective sphingosine 1-phosphate (S1P) receptor1,5 modulator, siponimod, is associated with reduced relative risk of confirmed disability progression, according to a study published online March 22 in The Lancet.

Ludwig Kappos, M.D., from the University of Basel in Switzerland, and colleagues conducted a phase 3 trial at 292 hospital clinics and specialized multiple sclerosis centers in 31 countries. Patients with SPMS and an Expanded Disability Status Scale score of 3.0 to 6.5 were randomized in a 2:1 ratio to once-daily oral siponimod 2 mg or placebo. A total of 1,645 patients were included in the analyses: 1,099 to the siponimod group and 546 to the placebo group; 903 and 424 patients completed the study, respectively.

The researchers found that 26 and 32 percent of patients receiving siponimod and placebo had three-month confirmed disability progression events (hazard ratio, 0.79; relative risk reduction, 21 percent). Adverse events occurred in 89 and 82 percent of patients taking siponimod and placebo, respectively; serious adverse events were reported for 18 and 15 percent, respectively.

"Siponimod reduced the risk of disability progression with a safety profile similar to that of other S1P modulators and is likely to be a useful treatment for SPMS," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Novartis, which manufactures siponimod and funded the study.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Access to In-Home Support Soon to Be Available for Seniors

Access to In-Home Support Soon to Be Available ...

Under Medicare Advantage, a health-related reason will be needed to qualify; costs will vary

USPSTF Recommends Screening Adults for Unhealthy Alcohol Use

USPSTF Recommends Screening Adults for Unhealthy Alcohol Use

Recommendation applies to all adults, including pregnant women; insufficient evidence for teens

AHA: Icosapent Ethyl Cuts CV Risk From Elevated Triglycerides

AHA: Icosapent Ethyl Cuts CV Risk From Elevated ...

Ischemic events reduced among patients with elevated triglycerides despite taking statins

is free, fast, and customized just for you!




Already a member?

Sign In Now »